Experts in pediatrics, GU cancer named to new posts
Leaders in the fields of pediatric urology and genitourinary cancer have been appointed to new positions at Nationwide Children’s Hospital, Thomas Jefferson University, and Prostate Oncology Specialists.
Leaders in the fields of pediatric urology and genitourinary cancer have been appointed to new positions at Nationwide Childrenâs Hospital, Thomas Jefferson University, and Prostate Oncology Specialists.
Joining the section of urology at Nationwide Childrenâs Hospital in Columbus, OH as director of robot-assisted laparoscopic surgery is Daniel B. Herz, MD. The robotic surgery program launched in January 2013 with an initial focus on urology.
Dr. Herz was most recently director of the section of pediatric urology at Childrenâs Hospital at Dartmouth, Lebanon, NH. Dr. Herz, whose expertise is in robot-assisted pediatric urologic surgery, received his medical degree from SUNY Health Science Center at Brooklyn and completed his residency at the University of Pittsburgh Medical Center. He completed a 2-year clinical and research fellowship in pediatric urology at the Hospital for Sick Children, University of Toronto.
At Thomas Jefferson, Mark Hurwitz, MD, has been appointed vice chair for quality, safety, and performance excellence and director of thermal oncology. Dr. Hurwitz, a recognized leader in thermal medicine and genitourinary oncology, previously served as director of regional program development for the department of radiation oncology at the Dana-Farber/Brigham and Womenâs Cancer Center, Boston.
In addition to his clinical leadership in thermal therapy, Dr. Hurwitz has interest in translational research on the immune effects of radiation and heat. His clinical and research focus is on advancement of leading-edge treatment strategies in genitourinary oncology. Upon completion of his residency at Johns Hopkins Hospital in Baltimore, he joined the faculty of Harvard Medical School, Boston, where he served as an associate professor.
Prostate Oncology Specialists, a multispecialty group in Marina del Ray, CA, announced that Jeffrey Turner, MD, has joined the prostate cancer specialist team. Dr. Turner is a board-certified internist and medical oncologist and will be specializing exclusively in prostate cancer.
Dr. Turner, who has been specializing in prostate cancer since 2009, worked in research at UCLA studying infectious disease and molecular biology. He earned his medical degree in Canada at Memorial University of Newfoundland and completed his internal medicine residency at the University of British Columbia, Vancouver and fellowship in medical oncology at the Medical University of South Carolina, Charleston.
Related Content
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
